PharmaCyte Biotech/$PMCB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PharmaCyte Biotech
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Ticker
$PMCB
Sector
Primary listing
Employees
2
Headquarters
Website
PMCB Metrics
BasicAdvanced
$7M
0.32
$3.19
-0.29
-
Price and volume
Market cap
$7M
Beta
-0.29
52-week high
$1.84
52-week low
$0.80
Average daily volume
119K
Financial strength
Current ratio
7.678
Quick ratio
6.6
Profitability
Management effectiveness
Return on assets (TTM)
-4.76%
Return on equity (TTM)
67.08%
Valuation
Price to earnings (TTM)
0.323
Price to book
0.13
Price to tangible book (TTM)
0.14
Price to free cash flow (TTM)
-2.535
Free cash flow yield (TTM)
-39.45%
Free cash flow per share (TTM)
-0.406
Growth
Earnings per share change (TTM)
-277.16%
3-year earnings per share growth (CAGR)
126.83%
10-year earnings per share growth (CAGR)
-17.24%
PMCB News
AllArticlesVideos
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
Business Wire2 weeks ago
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
Business Wire4 weeks ago
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PharmaCyte Biotech stock?
PharmaCyte Biotech (PMCB) has a market cap of $7M as of September 16, 2025.
What is the P/E ratio for PharmaCyte Biotech stock?
The price to earnings (P/E) ratio for PharmaCyte Biotech (PMCB) stock is 0.32 as of September 16, 2025.
Does PharmaCyte Biotech stock pay dividends?
No, PharmaCyte Biotech (PMCB) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next PharmaCyte Biotech dividend payment date?
PharmaCyte Biotech (PMCB) stock does not pay dividends to its shareholders.
What is the beta indicator for PharmaCyte Biotech?
PharmaCyte Biotech (PMCB) has a beta rating of -0.29. This means that it has an inverse relation to market volatility.